SOHO 2023 | Pre-MEASURE study: assessing the role of NGS MRD in patients with AML receiving SCT
Laura Dillon
• 8 Sep 2023
Laura Dillon, PhD, FACMG, National Institutes of Health, Bethesda, MD, discusses the pre-MEASURE study, which is assessing the use of next generation sequencing (NGS) to detect measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) receiving a stem cell transplant (SCT). Dr Dillon comments on the impact of NPM1 and FLT3-ITD mutations on patient outcomes. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
